188440-21-3

Basic information

• Product Name: 3-Bromomethyl-2,4-dichlorobenzenesulfonyl chloride
• Synonyms: 3-Bromomethyl-2,4-dichlorobenzenesulfonyl chloride;3-(BROMOMETHYL)-2,4-DICHLOROBENZENE-1-SULFONYL CHLORIDE(WXG01139);BENZENESULFONYL CHLORIDE, 3-(BROMOMETHYL)-2,4-DICHLORO-
• CAS NO: 188440-21-3
• Molecular Formula: C₇H₄BrCl₃O₂S
• Molecular Weight: 338
• Mol File: 188440-21-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-Bromomethyl-2,4-dichlorobenzenesulfonyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromomethyl-2,4-dichlorobenzenesulfonyl chloride(188440-21-3)
• EPA Substance Registry System: 3-Bromomethyl-2,4-dichlorobenzenesulfonyl chloride(188440-21-3)

Safety Data

• Hazardous Substances Data: 188440-21-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromomethyl-2,4-dichlorobenzenesulfonyl chloride is used as a reagent in organic synthesis for the development of new pharmaceutical compounds. Its reactivity and electrophilic nature make it an important building block for the synthesis of biologically active molecules with potential therapeutic applications.
Used in Agrochemical Industry:
3-Bromomethyl-2,4-dichlorobenzenesulfonyl chloride is used as a precursor in the synthesis of agrochemicals. Its versatility and reactivity contribute to the development of new compounds with potential applications in agriculture, such as pesticides and herbicides.
Used in Specialty Chemicals Production:
3-Bromomethyl-2,4-dichlorobenzenesulfonyl chloride is used as a precursor for the production of various specialty chemicals. Its unique structure and reactivity enable the creation of novel compounds with specific properties for use in different industries, such as dyes, polymers, and coatings.

Upstream product

• 69145-58-0 2,4-Dichloro-3-methylbenzenesulfonyl chloride 

Downstream Products

• 188440-24-6 N-[(3-Bromomethyl-2,4-dichlorophenyl)sulfonyl]-(D,L)-proline Methyl Ester 
• 635697-97-1 lithium (R)-2-[2,4-dichloro-3-(2,4-dimethyl-8-quinolinyloxymethyl)-benzenesulfonamido]-2-methylbutanoate 
• 883969-06-0 4-(3-bromomethyl-2,4-dichloro-benzenesulfonylamino)-tetrahydro-pyran-4-carboxylic acid methyl ester 
• 928850-81-1 {4-benzyloxycarbonylamino-1-[2-(4-{1-[2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonylamino]-cyclopentanecarbonyl}-piperazin-1-yl)-2-oxo-ethyl]-butyl}-trimethyl-ammonium 

Relevant articles and documents

Discovery of novel quinoline sulphonamide derivatives as potent, selective and orally active RORγ inverse agonists

A high-throughput screen against Inventiva's compound library using a Gal4/RORγ-LBD luciferase reporter gene assay led to the discovery of a new series of quinoline sulphonamides as RORγ inhibitors, eventually giving rise to a lead compound having an inte

Design and synthesis of novel sulfonamide-containing bradykinin hB 2 receptor antagonists. 2. Synthesis and structure-activity relationships of α,α-cycloalkylglycine sulfonamides

Recently we reported on the design and synthesis of a novel class of selective nonpeptide bradykinin (BK) B2 receptor antagonists (J. Med. Chem. 2006, 3602-3613). This work led to the discovery of MEN 15442, an antagonist with subnanomolar affinity for the human B2 receptor (hB2R), which also displayed significant and prolonged activity in vivo (for up to 210 min) against BK-induced bronchoconstriction in the guinea-pig at a dose of 300 nmol/kg (it), while demonstrating only a slight effect on BK-induced hypotension. Here we describe the further optimization of this series of compounds aimed at maximizing the effect on bronchoconstriction and minimizing the effect on hypotension, with a view to developing topically delivered drugs for airway diseases. The work led to the discovery of MEN 16132, a compound which, after intratracheal or aerosol administration, inhibited, in a dose-dependent manner, BK-induced bronchoconstricton in the airways, while showing minimal systemic activity. This compound was selected as a preclinical candidate for the topical treatment of airway diseases involving kinin B2 receptor stimulation.

NON-PEPTIDE BRADYKININ ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREFROM

Non-peptide compounds having activity as selective antagonists of bradykinin (BK) B2 receptor. The compounds are chemically characterized by the presence of an amino acid alpha substituted with a cyclic group and by a tetraalkylammonium group.

Heterocyclic benzenesulphonamide compounds as bradykinine antagonists

The invention concerns compounds selected among the group consisting of (i) compounds of formula (I) wherein: Het1 represents a nitrogenous heterocycle with 5 apices, in particular imidazole, pyrazole, or triazole; Het2 represents a nitrogenous heterocycle with 4, 5 or 6 apices, selected among the heterocycles: (II) wherein R1and R2are defined as mentioned in the description; and (ii) their additive salts. The invention also concerns the method for preparing said compounds and their use in therapy, in particular for treating pathologies involving bradykinine.

Benzenesulfonamide derivatives as bradykinin antagonists

PCT No. PCT/FR96/01262 Sec. 371 Date Apr. 7, 1997 Sec. 102(e) Date Apr. 7, 1997 PCT Filed Aug. 7, 1996 PCT Pub. No. WO97/07115 PCT Pub. Date Feb. 27, 1997The present invention relates to compounds selected from the group consisting of the compounds of formula (I): X is a halogen atom, A is -CH2-, -CH(OH)-, -CH(NH-COCH3)- or S, R is H, CO2H, CO2-B-R1 or CO-N(R2)-B-R1, B is linear, branched or cyclic C1-C10-alkylene, R1 is H, CH2OH, CH2-O-CH3, CH2-NR3R4 or phenyl, R2 is H or C1-C4-alkyl, R3 is H or linear, branched or cyclic C1-C10-alkyl, R4 is H or linear or branched C1-C10-alkyl, it being possible for NR3R4 to be a saturated heterocyclic radical having from 5 to 8 ring members and containing at least one nitrogen atom, and the carbon carrying the substituent R, when Q is saturated, can be of indeterminate (R,S) configuration or of determinate (R) or (S) configuration; and their addition salts. It further relates to their use in therapeutics, especially for pathological conditions involving bradykinin.